O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-0.47%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.5M
AUM Growth
+$5.5M
(-100%)
Cap. Flow
-$176M
Cap. Flow
% of AUM
-3,203.7%
Top 10 Holdings %
Top 10 Hldgs %
32.29%
Holding
153
New
11
Increased
26
Reduced
36
Closed
14
Top Buys
| 1 |
SVA
Sinovac Biotech, Ltd
SVA
|
$349K |
| 2 |
Xenon Pharmaceuticals
XENE
|
$19.6K |
| 3 |
Mersana Therapeutics
MRSN
|
$19.5K |
| 4 |
Travere Therapeutics
TVTX
|
$18.7K |
| 5 |
Progyny
PGNY
|
$18.2K |
Top Sells
| 1 |
DexCom
DXCM
|
$76.7M |
| 2 |
NSTG
NanoString Technologies, Inc.
NSTG
|
$40.2M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
$16.5M |
| 4 |
Illumina
ILMN
|
$15.8M |
| 5 |
Galapagos
GLPG
|
$12.9M |
Sector Composition
| 1 | Healthcare | 98.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
| $350K | 6.33% | +2,718,735 | New | +$349K |
|
2
Bristol-Myers Squibb
BMY
$96B
| $194K | 3.51% | 2,518,700 -89,000 | -3% | -$6.85K |
|
3
Humana
HUM
$36.5B
| $171K | 3.1% | 365,700 -16,000 | -4% | -$7.49K |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $168K | 3.05% | 2,108,555 -88,000 | -4% | -$7.02K |
|
5
Boston Scientific
BSX
$156B
| $163K | 2.95% | 4,369,500 -230,000 | -5% | -$8.57K |
|
|
TPTX
6
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $151K | 2.74% | 2,012,250 -6,700 | -0.3% | -$504 |
|
|
SWTX
7
DELISTED
SpringWorks Therapeutics
SWTX
| $148K | 2.69% | 6,028,307 | – | – |
|
8
UnitedHealth
UNH
$281B
| $144K | 2.62% | 281,200 -13,000 | -4% | -$6.68K |
|
9
Pfizer
PFE
$141B
| $144K | 2.61% | 2,744,000 -1,161,500 | -30% | -$60.9K |
|
10
BioMarin Pharmaceuticals
BMRN
$11.2B
| $141K | 2.55% | 1,699,710 +52,680 | +3% | +$4.37K |
|
11
AbbVie
ABBV
$372B
| $122K | 2.22% | 799,800 -115,800 | -13% | -$17.7K |
|
|
SGEN
12
DELISTED
Seagen Inc. Common Stock
SGEN
| $122K | 2.2% | 687,500 +19,800 | +3% | +$3.5K |
|
13
Edgewise Therapeutics
EWTX
$1.51B
| $112K | 2.03% | 14,082,680 +138,000 | +1% | +$1.1K |
|
14
Vertex Pharmaceuticals
VRTX
$100B
| $109K | 1.98% | 387,200 -13,000 | -3% | -$3.66K |
|
15
Adicet Bio
ACET
$59.9M
| $109K | 1.97% | 7,447,141 | – | – |
|
|
SRRA
16
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $108K | 1.96% | 1,964,770 | – | – |
|
|
BHVN
17
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $105K | 1.9% | 719,034 | – | – |
|
18
Intuitive Surgical
ISRG
$170B
| $104K | 1.88% | 517,200 -17,000 | -3% | -$3.41K |
|
19
Arcutis Biotherapeutics
ARQT
$1.86B
| $102K | 1.85% | 4,781,646 -1,292,204 | -21% | -$27.5K |
|
|
TCDA
20
DELISTED
Tricida, Inc. Common Stock
TCDA
| $99.5K | 1.8% | 10,280,947 | – | – |
|
21
Edwards Lifesciences
EW
$47.8B
| $96.2K | 1.74% | 1,011,300 -40,000 | -4% | -$3.8K |
|
|
THRX
22
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $94.2K | 1.71% | 17,041,668 | – | – |
|
23
PMV Pharmaceuticals
PMVP
$74.2M
| $93.5K | 1.69% | 6,563,077 -292,346 | -4% | -$4.17K |
|
24
Stryker
SYK
$150B
| $87.7K | 1.59% | 441,100 -16,000 | -4% | -$3.18K |
|
25
Neurocrine Biosciences
NBIX
$13.8B
| $82.8K | 1.5% | 849,545 -25,970 | -3% | -$2.53K |
|